Q-omics provides the consensus-scored ZNF286A profile across patient tissues and cancer cell-line models. ZNF286A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF286A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZNF286A RNA expression shows 20,004 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where ZNF286A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF286A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF286A survival associations across molecular data types. ZNF286A RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF286A RNA expression–survival associations across cancer types. High ZNF286A expression shows unfavorable associations in LIHC, KICH, ACC, MESO, UCEC and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF286A RNA expression.
This table summarizes ZNF286A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF286A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF286A shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, LIHC and LUSC. The HNSC box plot shows higher ZNF286A RNA expression in tumor versus normal tissue (log2 FC = +0.595, t-test p < 0.001).
This table shows molecular features associated with ZNF286A in patient tissues and cancer cell lines. In patient samples, ZNF286A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF286A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
